Argenx Clinical Trial on Post-COVID POTS

This podcast episode discusses an ongoing clinical trial by Argenx focused on treating Post-COVID POTS using a medication called efgartigimod. This trial aims to assess the safety and efficacy of efgartigimod, which the company hypothesizes will help by depleting autoantibodies that contribute to POTS symptoms. Dr. Artur Fedorowski supports the concept that many POTS cases may have an autoimmune cause, where inappropriate autoantibodies disrupt cardiovascular functions. Dr. Joost Van Middendorp outlines that the trial involves 42 participants and will compare efgartigimod to a placebo over 24 weeks. The episode also touches on the new Malmo POTS symptom score, a tool which helps in evaluating symptom severity and improvement over time. The experts express optimism that findings could represent significant steps forward in POTS treatment, especially for those whose conditions developed post-infection.